Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial data NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 ...
CDT Equity Inc. has deployed an AI-led drug repurposing strategy for its portfolio and identified a new biological target and novel therapeutic indication for its lead program, AZD-1656 (and its ...
With a robust patent portfolio already in place, CDT has initiated several pre-clinical studies to explore the potential of AZD1656 in these untapped therapeutic areas. The results of the first of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback